Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Everolimus (Afinitor) for Neuroendocrine tumors of Gastrointestinal or Lung origin
(Pending Submission as of April 27, 2016)

Ibrutinib (Imbruvica) for Waldenström’s Macroglobulinemia
(Open for Input on Submission until May 5, 2016)

Daratumumab (TBD) for Multiple Myeloma
(Open for Input on Submission until May 5, 2016)

Pembrolizumab (Keytruda) for Non-Small Cell Lung Cancer (NSCLC)
(Open for Input on Submission until May 5, 2016)

Ibrutinib (Imbruvica) for previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
(Open for Input on Submission until May 4, 2016)

Lenvatinib (Lenvima) for Differentiated Thyroid Cancer
(Open for Input on Submission until May 2, 2016)

 

Find a Drug Review